Thyrocare Share Price in Focus; Completes Bonus Share Allotment for Eligible Shareholders

The Stakeholders Relationship Committee of Thyrocare Technologies Limited has approved and allotted 10,61,07,794 fully paid-up bonus equity shares at its meeting held on December 1, 2025. 

The allotment has been made in the ratio of 2:1, meaning shareholders will receive 2 new equity shares of ₹10 each for every 1 existing equity share they held as on the record date of November 28, 2025. All eligible members whose names appeared in the Register of Members or beneficial owners have now been credited with the bonus shares.

Details of the Bonus Issue and Capital Enhancement

The bonus issue has significantly expanded the company’s equity base. Prior to the bonus allotment, the paid-up share capital stood at 5,30,53,897 equity shares, amounting to ₹53,05,38,970. Following the issuance of 10,61,07,794 additional shares, the total paid-up equity share capital has risen sharply to 15,91,61,691 equity shares, translating to a revised value of ₹1,59,16,16,910.

This expansion of capital reflects the company’s strong financial position and is aimed at enhancing liquidity, increasing retail participation, and rewarding long-term shareholders. Bonus shares are issued from the company’s free reserves and do not involve any outflow of cash from the investor’s end.

Parity and Rights of the Newly Issued Shares

The bonus equity shares will rank pari-passu with the existing equity shares in every respect. This means the new shares will carry equal voting rights, dividend eligibility, and all other shareholder entitlements similar to the old shares. With the increased number of outstanding shares, the company aims to further broaden its shareholder base while maintaining strong governance and capital discipline.

Thyrocare Share Price Performance

On December 1, 2025, Thyrocare share price (NSE: THYROCARE) opened at ₹489.00, down from its previous close of ₹495.70. At 12:27 PM, the share price of Thyrocare was trading at ₹486.75, down by 1.81% on the NSE.

Also Read: Meesho IPO Set to Open on December 3, 2025!

Conclusion

The 2:1 bonus share allotment marks a significant milestone for Thyrocare Technologies, underscoring its commitment to rewarding shareholders and enhancing stock liquidity. With the paid-up capital tripling post-issue, the company has strengthened the equity structure while ensuring that all shareholders benefit proportionally from its growth outlook.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.